



PRODUCT: **ERVEBO®**

COMPANY: Merck & Co., Inc.

THERAPEUTIC AREA & INDICATION:

First preventive vaccine against the disease
caused by the Zaire ebolavirus in adults

ABOUT THE PRODUCT

ERVEBO® is a recombinant, virally-vectored, replication-competent, attenuated live vaccine that induces protective immune responses within 10 days of receipt of a single dose. This is the first rVSV-based product to be licensed. The rapidity of protection and efficacy after a single dose makes ERVEBO® a life-saving tool for responding to future Ebola outbreaks.

The WHO-sponsored trial adapted a ring vaccination strategy to support the robust scientific evaluation of the efficacy of ERVEBO®. This innovation focused the intervention in populations at highest risk of developing disease and led to licensure in several African countries within 60 days of the first approval.